Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference
02 févr. 2022 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Expands Leadership Team
01 févr. 2022 16h01 HE
|
Aclaris Therapeutics, Inc.
Appoints James Loerop as Chief Business Officer WAYNE, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on...
Aclaris Therapeutics Provides R&D Update
11 janv. 2022 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
27 déc. 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine
03 déc. 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021
18 nov. 2021 16h01 HE
|
Aclaris Therapeutics, Inc.
Investigational New Drug Application for ATI-2138 Allowed WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused...
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
03 nov. 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
02 nov. 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
Investigational New Drug Application for ATI-2138 for the Treatment of Psoriasis Submitted in October 2021Planning to Initiate Phase 2b Trial of Zunsemetinib (ATI-450) in Moderate to Severe Rheumatoid...
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
27 août 2021 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
26 août 2021 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...